Sign Out
Women of childbearing potential: Women should be advised to avoid becoming pregnant while receiving capecitabine. If in case the patient got pregnant, the potential hazard to the fetus must be explained.
Use in Pregnancy: Pregnancy Category D: There are no data on the safety of capecitabine in pregnant women; however, in animal studies, it caused embryolethality and teratogenicity that are expected effects of fluoropyrimidine derivatives. Thus, pregnancy should be avoided while receiving treatment with capecitabine.
Use in Lactation: In an animal study, capecitabine and its metabolites were found in the milk of lactating mice. In human breast milk, however, it is unknown. Hence, breastfeeding should be discontinued while receiving treatment with capecitabine.
Continue with Google